

Frank Atherton
Prif Swyddog Meddygol/Cyfarwyddwr Meddygol, GIG Cymru
Chief Medical Officer/Medical Director NHS Wales

Andrew Evans
Prif Swyddog Fferyllol
Chief Pharmaceutical Officer



Llywodraeth Cymru
Welsh Government

To:

All NHS Wales clinical staff

Our Ref: AE/qA1422915

18 March 2020

Dear, Colleagues

Anti-inflammatory medications

There has been concern about the use of non-steroidal anti-inflammatory medications (NSAIDs) in relation to Covid-19 following a statement by the French Health Minister (a clinician) advising against the use of ibuprofen.

This statement was based on provisional information reported from French care settings which UK authorities have not seen and is, to date, unpublished. There is no current literature on the impact of NSAIDs use in Covid-19.

There appears to be some evidence for SARS 1 that there may be an adverse impact on pneumonia. There is also some literature suggesting NSAIDs may increase complications from simple acute respiratory infections or slow recovery. However the evidence is not conclusive overall.

There appears to be no evidence that NSAIDs increase the chance of acquiring Covid-19. In view of the current lack of clarity the Committee of Human Medicines (an advisory body of MHRA) and NICE have been asked to review the evidence. It is therefore suggested that, in the interim, for patients, who have confirmed Covid-19 or believe they have Covid-19, that they use paracetamol in preference to NSAIDs.

Those currently on NSAIDs for other medical reasons (e.g. arthritis) should not stop them.

This position will be kept under constant review and we will inform you of any changes to the above advice.

Yours sincerely



Dr Frank Atherton
Prif Swyddog Meddygol/Cyfarwyddwr
Meddygol, GIG Cymru
Chief Medical Officer/ Medical Director
NHS Wales
Llywodraeth Cymru/
Welsh Government



Andrew Evans
Prif Swyddog Fferyllol/Chief
Pharmaceutical Officer
Llywodraeth Cymru/
Welsh Government